Company intelligence / Profile preview

PulseSight Therapeutics

Paris, Île-de-France, Francepulsesight.com ↗

Ownership: Private
Development stage: Phase 1

Overview

PulseSight’s proprietary non‑viral gene therapy platform has demonstrated safety and long-lasting benefit in a prior Phase I/II study for uveitis. The lead program PST‑611 is entering a first-in-human trial in dry AMD/GA, aiming to confirm safety and biological activity. Preclinical data show strong efficacy by restoring iron homeostasis and reducing retinal degeneration. The second program, PST‑809, targets wet AMD with dual antiangiogenic action; preclinical studies indicate superior efficacy over current standards.

Therapeutic areas: Ophthalmology
Modalities: Non-viral gene therapies (plasmid DNA)Vectorized therapeutic proteins delivered via electro-transfection device
Industry: Biotech

Drug pipeline

1 asset

EYS611

Partnerships

Pureos BioVentures (lead investor/supporter)ND Capital (investor/supporter)Korea Investment Partners/KIP (investor/supporter)

Beyond the preview

Go deeper on PulseSight Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PulseSight Therapeutics.

Explore the full profile